Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment

Next Previous
Trial Profile

Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gilteritinib (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms SEQUENCE

Most Recent Events

  • 29 May 2025 Status changed from not yet recruiting to recruiting.
  • 26 Feb 2025 Planned End Date changed from 1 Jan 2030 to 1 Apr 2030.
  • 26 Feb 2025 Planned primary completion date changed from 1 Jan 2029 to 1 Apr 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top